Serum microRNA Landscape in Eosinophilic Granulomatosis with Polyangiitis: A Hypothesis-Generating Reference Dataset

Authors: Kamide, Yosuke; Sonehara, Kyuto; Ueki, Shigeharu; Furukawa, Yoshihiro; Nakamura, Yuto; Fukutomi, Yuma; Sekiya, Kiyoshi; Okada, Yukinori; Taniguchi, Masami

Source journal: International archives of allergy and immunology (2026-11-19)

DOI: 10.1159/iaa/adfag045

Abstract

INTRODUCTION: Eosinophilic granulomatosis with polyangiitis (EGPA) is an eosinophilic vasculitis arising against a background of adult-onset asthma. We investigated circulating microRNA (miRNA) profiles in EGPA and integrated them with previously reported serum protein data. METHODS: In this retrospective, cross-sectional study, archived sera from 14 patients with active, glucocorticoid-naive EGPA and 20 with severe eosinophilic asthma without EGPA were profiled on a 2,588-miRNA microarray. Differential expression among 1,777 quantifiable miRNAs was assessed with limma, adjusting for sex and RNA integrity number; significance required both a Benjamini-Hochberg false discovery rate below 0.05 and a Bonferroni-corrected p below 0.05. TargetScan-predicted target genes were intersected with 29 serum proteins previously shown to differ between the same groups. Two further paired analyses, each performed in a separate group of patients with EGPA, compared active disease with the glucocorticoid-treated phase (n = 11) and samples before versus after mepolizumab (n = 13). RESULTS: Eight miRNAs met both criteria: hsa-miR-3126-5p, hsa-miR-921, hsa-miR-6836-5p and hsa-miR-668-5p were lower in EGPA, and hsa-miR-6857-3p, hsa-miR-1260a, hsa-miR-603 and hsa-miR-12125 were higher (within-cohort areas under the curve, 0.82-0.94). Fourteen of the 29 proteins were encoded by predicted target genes. Only hsa-miR-3678-3p changed after glucocorticoid treatment; no miRNA changed after mepolizumab, and none of the eight EGPA-associated miRNAs changed with either treatment. CONCLUSION: This exploratory study identifies circulating miRNA differences between EGPA and severe eosinophilic asthma, and the complete result table is provided as a reference resource. Independent validation is required to establish their biological and clinical significance. TRIAL REGISTRATION: UMIN000040163.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.